BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 7912526)

  • 1. Taxol commercial supply strategy.
    DeFuria MD; Horovitz Z
    J Natl Cancer Inst Monogr; 1993; (15):195-8. PubMed ID: 7912526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Taxol--a new cytostatic drug for therapy of ovarian and breast cancer].
    Meden H; Rath W; Kuhn W
    Geburtshilfe Frauenheilkd; 1994 Apr; 54(4):187-93. PubMed ID: 7912212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Closing Remarks.
    Reed E
    Oncologist; 1996; 1(4):276-277. PubMed ID: 10388002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological activity of protaxols.
    Nicolaou KC; Riemer C; Kerr MA; Rideout D; Wrasidlo W
    Nature; 1993 Jul; 364(6436):464-6. PubMed ID: 8101355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.
    Lee FY; Borzilleri R; Fairchild CR; Kim SH; Long BH; Reventos-Suarez C; Vite GD; Rose WC; Kramer RA
    Clin Cancer Res; 2001 May; 7(5):1429-37. PubMed ID: 11350914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total synthesis of taxol.
    Nicolaou KC; Yang Z; Liu JJ; Ueno H; Nantermet PG; Guy RK; Claiborne CF; Renaud J; Couladouros EA; Paulvannan K
    Nature; 1994 Feb; 367(6464):630-4. PubMed ID: 7906395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel: a new antimitotic chemotherapeutic agent.
    Gotaskie GE; Andreassi BF
    Cancer Pract; 1994; 2(1):27-33. PubMed ID: 7914453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical development of paclitaxel: a successful collaboration of academia, industry and the National Cancer Institute.
    Donehower RC
    Stem Cells; 1996 Jan; 14(1):25-8. PubMed ID: 8820947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience.
    Sledge GW; Robert N; Sparano JA; Cobeligh M; Goldstein LJ; Neuberg D; Rowinsky E; Baughman C; McCaskill-Stevens W
    Semin Oncol; 1994 Oct; 21(5 Suppl 8):15-8. PubMed ID: 7939756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Clinical Development of Paclitaxel: A Successful Collaboration of Academia, Industry and the National Cancer Institute.
    Donehower RC
    Oncologist; 1996; 1(4):240-243. PubMed ID: 10387996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel: current developmental approaches of the National Cancer Institute.
    Arbuck SG
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):55-63. PubMed ID: 8643972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel plus carboplatin in the treatment of ovarian cancer.
    Ozols RF
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):84-9. PubMed ID: 10190787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Paclitaxel (Taxol)].
    Hájek R
    Cas Lek Cesk; 1996 Jun; 135(12):393-6. PubMed ID: 8706079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorescent taxoids.
    Guy R; Scott Z; Sloboda R; Nicolaou K
    Chem Biol; 1996 Dec; 3(12):1021-31. PubMed ID: 9000007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future directions of paclitaxel-based therapy of breast cancer.
    Gianni L
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-91-S17-96. PubMed ID: 9374103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells.
    Parker RJ; Dabholkar MD; Lee KB; Bostick-Bruton F; Reed E
    J Natl Cancer Inst Monogr; 1993; (15):83-8. PubMed ID: 7912534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.